Clinical and Pathologic Profiles of Esophageal Cancer in Mozambique: A Study of Consecutive Patients Admitted to Maputo Central Hospital

• Type: Article in International Scientific Journal
• Date: 2018

Authors

Come, J (Author) Other; Castro, C (Author) Other; Morais, A (Author) Other; Cossa, M (Author) Other; Modcoicar, P (Author) Other; Tulsidas, S (Author) Other; Cunha, L (Author) Other; Lobo, V (Author) Other; Morals, AG (Author) Other; Cotton, S (Author) Other; Lunet N (Author) FMUP; Carrilho, C (Author) Other; Santos, LL (Author) Other

Journal

The Journal is awaiting validation by the Administrative Services.

Title: JOURNAL OF GLOBAL ONCOLOGY

Vol. 4

Pages: 1-9

ISSN: 2378-9506

Indexing

ISI Web of Knowledge - 20 Citations

Scopus - 18 Citations

Other information

Authenticus ID: P-00Q-CRB

DOI: 10.1200/jgo.18.00147

Abstract (EN): Purpose Eastern Africa was recently described as a high-incidence geographic area for esophageal cancer. Mozambique is included in this region. This study aimed to characterize this malignant disease at Maputo Central Hospital (MCH) to develop a global program for esophageal cancer management in Mozambique. Methods MCH records from between 2012 and 2016 were used to assess the clinical, pathologic, and outcome profiles of esophageal tumors. A descriptive analysis of data collected was performed. Overall survival was evaluated using Kaplan-Meier curves. Results In the study, 522 consecutive patient cases of esophageal cancer were recorded. The median patient age was 56.1 years (range, 27 to 97 years); 291 (55.7%) patients were women, and 230 (44.1%) were men. Regarding tumor site, 113 patients (21.6%) had a tumor in the lower third, 154 (29.5%) in the middle, and 50 (9.6%) in the upper third of the esophagus; in the remaining 196 (37.5%), tumor site was unknown. Squamous cell carcinoma comprised 94.4% of cases with documented histopathology (74.9% of the sample). Surgical treatment was possible in 32 patients (6.1%). Disease stage was documented only in these 32 surgical patients; 28.1%, 53.1%, and 18.8% had stage I, II, and III disease, respectively. The remaining patient cases seemed to involve clinically advanced tumors. The median follow-up time was of 1.6 months. The median survival time was of 3.5 months for all patients; for patients treated with curative intent, it was of 8.7 months. Conclusion Esophageal carcinoma is a common malignant tumor at MCH and is diagnosed in the advanced stages resulting in poor prognosis. Therefore, implementation of an Esophageal Cancer Program in Mozambique is essential. (C) 2018 by American Society of Clinical Oncology

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 9